Arcellx, Inc.
Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical tr…
Biotechnology
US, Gaithersburg [HQ]
Similar Stocks · Benchmarked Analysis · Peer Group
Peer Group Analysis
Similar Stocks · Benchmarked Analysis · Peer GroupA quick analysis that compared Arcellx, Inc. (ACLX) to it's peer group, including competitors as well as it's industry. All monetary values in mil. except volume - volume is in thousands.
| Company | Price | Change | Volume, Avg. | Market Cap. | Revenue | Profit Net | Earnings | Free Cash Flow | Dividend Yield | P/E | EPS | Gross Margin % | Net Margin % | ROE % | ROA % | Quick Ratio % | Shares Outstanding | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Biotechnology Average | - - | - - | - - | 37,392.90 | 12,864.92 | 593.38 | 292.34 | -1,061.34 | 0.00 | 23.3585 | 41.96 | -0.7816 | -19.5541 | -0.07 | -0.07 | 6.7133 | - - | ||
| Maximum | - - | - - | - - | 1,535,067.00 | 609,984.00 | 35,800.00 | 99,050.00 | 5,421.00 | 0.02 | 1,336.3467 | 2,849.43 | 3.0051 | 85.3485 | 0.38 | 8.35 | 61.5621 | - - | ||
| Minimum | - - | - - | - - | 0.00 | 0.00 | -10,603.00 | -56,335.00 | -50,658.00 | 0.00 | -164.8536 | -132.82 | -101.7758 | -1,444.7800 | -1.56 | -12.64 | 0.0844 | - - | ||
| Nuvalent, Inc. NUVL | 92.99 | 0.26 0.28% | 14 vs. 535 | 6,607.00 | 0.00 | -44.00 | -36.00 | -330.00 | -0.6900 | -27.7942 | 0.0000 | 0.0000 | 0.0000 | -0.0659 | -0.0628 | 20.6970 | 71.00 | ||
| Arcellx, Inc. ACLX | 87.82 | 0.60 0.69% | 14 vs. 539 | 4,748.00 | 39.00 | -7.00 | -38.00 | -396.00 | -0.1400 | -122.7330 | 0.0000 | 0.9790 | -0.1834 | -0.0145 | -0.0092 | 5.3496 | 54.00 | ||
More Due Diligence
Leverage our visualization and data tables to compare over 25 years of financial data for AAPL and its peers.